-- The Group's net revenues increased 26 percent with respect to the same period last year.
-- The Biopharmaceutical business reported 59 percent growth in sales with respect to September 2009, and consumer chemicals sales rose 6 percent in the same period.
-- Zeltia Group maintains positive EBITDA in the first nine months of 2010.
MADRID, Oct. 28 /PRNewswire/ -- Group revenues totaled 120 million euro (approximately 167 million USD*) in the first nine months of 2010, i.e. an increase of 26.1 percent with respect to the same period last year (95.19 million euro or approximately 132.6 million USD).
Net sales in the Biopharmaceutical business amounted to 56.9 million euro or approximately 79.3 million USD (35.8 million euro or approximately 49.9 million USD in the first nine months of 2009), of which 51.8 million (approximately 72.1 million USD) correspond to Yondelis sales (30.4 million euro or approximately 42.3 million USD in 9M09). Genomica's sales totaled 5.1 million euro (approximately 7.1 million USD).
The Consumer chemicals division reported sales of 62.2 million euro or approximately 86.6 million USD (58.6 million euro or approximately 81.6 million USD in 9M09). This division accounted for 51.8 percent of total group revenues in the first nine months of 2010 (61.5 percent in 9M09).
The Group maintained positive EBITDA of 2.7 million euro (approximately 3.8 million USD) in 9M10, driven by steadily rising sales since the beginning of the year.
Net income attributable to the parent company improved 63 percent with respect to September 2009.
Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two profitable companies that are leaders in their respective market segments.
For more information, Zeltia +34 91 444 4500
This note is also available at Zeltia's web site: www.zeltia.com
* All original figures are in Euros; dollar figures are estimated using the exchange rate: 1.3928.